Pu Erh Tea Benefits – Diabetes Prevention and Blood Sugar Reduction

Recent press briefing by the Pu’er city government, has confirmed that the ancient Pu Erh Tea does indeed, lower blood sugar levels, preventing people from getting Diabetes.

The discovery was made by scientists working at the Jilin University, Changchun Science and Technology University in the Yunnan provice of China. The study lasted for two years, it started with 20 genetically made obese rats, and the researches fed 10 of the rats with pu erh tea while the other 10 rats were not given any.

The results were astounding, 11 months after the 10 rats that were fed with the tea survived while the other 10 got infections, and sores before dying. The healthy rats had no traces of any illnesses, which concluded that the tea was effective.

However, they had one more test. They wanted to compare Rosiglitazone, a widely used medicine to reduce blood sugar levels, with Pu’er tea. The scinetists then split the rets in two groups, one was fed with Rosiglitazone and the other with Pu’er tea.

What they discovered was that the tea was allot more effective. Blood sugar levels had dropped down by 42%, and 36.5% with the other group of rats that was fed with Rosiglitazone. Amazingly enough, the rats that was fed with Pu’er tea lost weight while the other group had absolutley no evidence of any weight loss.

This is what I’ve been saying for a long time. The nature provides what we, or animals needs heal. After this research was concluded, the scientists sought out diabetics to aid them. They got 120 volunteers, and were asked to drink Pu’er on a regular basis, and completely stop taking their medications, while doing no chances to their diet.

When the reports came in, an whopping 70% of the participants said that their blood sugar levels were lowered to below 7 mmol/L, and about an average decrease of 35%.

Sheng Jun, the deputy mayor of Pu’er city says that Yunnan has one of China’s best longevity rates. He also states: “Yunnan has the lowest incidence of cancer, Pu’er city has the lowest number of cancer patients.”

Type 2 Diabetes – Insulin Sensitivity Response Differs in Obese Adolescents And Obese Adults

Teenagers often respond poorly to medications designed to increase insulin sensibility, compared with an adult. It has been thought adolescents have more severe cases than adults. Or could there be some other difference?

In July of 2017, the journal Pediatric Diabetes reported on a study performed at the University of Pittsburgh in the United States and different research centers in the USA and Lebanon. The study included…

  • 34 obese adolescents, and
  • 17 obese adults.

Both groups had a comparable percentage of body fat, but the children had twice the insulin concentration, usually interpreted as higher insulin resistance. (Obesity is associated with low insulin sensitivity). Other tests also showed lower insulin sensitivity in the adolescents, as well as lower high-density lipoprotein (good cholesterol or HDL). From these results, it was concluded obese youths and adults were different in that the former were more resistant to insulin than adults which could explain why adults respond better to drugs designed to increase insulin sensitivity.

The list of medications known to increase insulin sensitivity include…

  • metformin and the thiazolidinediones. The latter is made up of Avandia, or rosiglitazone, Actos, also known as pioglitazone.
  • another glitazone, Rezulin, or troglitazone, was removed from the market after causing liver damage. The glitazones, as they are called for short, build up insulin sensitivity by working directly with fat cells, liver cells, and muscle cells. The process involves fatty acids in the body.

Metformin or Glucophage is usually the first drug of choice for Type 2 diabetes. It works by encouraging the pancreas to make a higher insulin response to the sugar intake and help the liver to make less sugar. Its safety lies in the fact it does not increase insulin until and unless there is a need. Hypoglycemia, or overly low blood sugar, is not a problem.

Type 2 diabetes rarely occurs in normal-weight individuals, so it is one good reason to maintain a healthy weight. The average body mass index (BMI) is between 18.5 and 24.9. Simple online calculators are available for finding your BMI. If it is higher than what is healthy, see your doctor for a weight-loss plan.

Substituting fruit for highly-processed baked goods and other desserts are a positive way of keeping your calorie intake down and fiber intake up. Filling up on salads before dinner is also helpful. If you make it a habit of eating out of control when eating with friends or family, going to the table later than everyone else and being one of the first to leave should help you reduce your calorie intake.

Are Medications for the Treatment of Diabetes Safe?

In February of 2008 the NHLBI announced that the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study would be stopped because of an increased risk of death in patients on intensive glucose lowering treatment regimens. 10,251 patients with Type 2 diabetes were being treated with a range of medications for glucose control and were divided into intensive versus standard glucose lowering groups.

There were 257 deaths in the group receiving intensive treatment to lower HbA1C (a marker of elevated blood glucose levels) to below 6% compared to 203 deaths in the standard treatment group (HbA1C 7-7.9%). Deaths included sudden death and cardiovascular causes. Reactions from medical experts included “surprise” and “shock”, and yet this should not have come as any surprise since the fact that glitazone medications used for diabetes, including Avandia (rosiglitazone) and Actos (pioglitazone) carry a cardiovascular risk was previously known. For example, last year an article in the New England Journal of Medicine showed that Avandia (rosiglitazone) increased heart attack risk by 43%. These drugs also cause fluid retention which increases the risk of heart failure. For instance, in the A Diabetes Outcome Progression Trial (ADOPT) 4360 patients with poorly controlled Type-2 diabetes were randomly assigned to four years of treatment with rosiglitazone, metformin, or glyburide. Rosiglitazone caused more heart failure than glyburide, and was associated with more weight gain (+4.8 kg-convert to pounds, v -2.9 kg for metformin) and fluid build up or edema (probable cause of the heart failure). 22 rosiglitazone patients developed heart failure, compared to 19 with metformin and 9 with glyburide.

In the PROspective pioglitAzone Clinical Trial in macroVascular Events (PROactive) Study, 5238 patients with Type-2 diabetes and evidence of vascular disease were randomly assigned to treatment with pioglitazone or placebo to be taken with their typical treatment regimen. There was no significant difference in the primary outcome of any vascular event; 281 patients on pioglitazone developed heart failure compared to 198 on placebo, a 42% increase which was highly statistically significant. Most people don’t know that glitazones cause weight gain and actually create new fat cells, making you more “fatty’. So in other words, they are promoting the thing that causes Type 2 diabetes in most people (i.e. weight gain), and causing the thing that we are trying to prevent by treating diabetes (i.e. heart attacks and heart failure). Not a very good deal.

Overall the older drugs for diabetes like glyburide are probably safer than the new drugs and cost much less. Diet and exercise are always the best way to prevent the development of Type 2 diabetes.